/content/dam/www/people-profile-photos/s/matthias-stephan/matthias-stephan-d.jpg
Stephan
Matthias Stephan, MD, PhD

Matthias Stephan, MD, PhD

  • Professor, Translational Science and Therapeutics Division, Fred Hutch
  • Member, Immunotherapy Integrated Research Center (IIRC), Fred Hutch
  • Professor, Division of Hematology and Oncology, University of Washington School of Medicine
  • Adjunct Assistant Professor, Bioengineering, University of Washington
206.667.6677
206.667.7983

Background

Dr. Matthias Stephan is an expert in immunobioengineering, a discipline that marries innovative materials engineering with strategies for improving immune-based therapies. He and his team are developing new approaches involving “smart” synthetic materials to boost the body’s natural ability to fight cancer. He developed a biodegradable sponge-like scaffold that can be loaded with cancer-fighting immune cells and immune-boosting drugs, then surgically implanted to help prevent disease recurrence or treat a tumor that cannot be safely removed. With Fred Hutch colleagues, Dr. Stephan is now developing and testing scaffolds to treat breast, ovarian, pancreatic and brain cancers. He is also developing nanoparticles to improve the curative power of an immunotherapy called T-cell therapy. For example, he is crafting nanoparticles to deliver molecules that would prime tumors for the therapy by shutting down their ability to evade or block the incoming T-cells.

Allen Distinguished Investigator, The Paul G. Allen Frontiers Group

Education

Postdoctoral Training, Massachusetts Institute of Technology, 2008-2012

PhD, Cornell University, 2008

MD, Medical University of Luebeck, 2002

Clinical Fellowship, Imperial College, 2000

Find a Clinical Trial

Stories

All news
Scientists see foam as starting point of a path to bedside gene therapy Bioengineer Dr. Matthias Stephan developed a quick-foaming solution that he hopes could one day turn gene therapy into an outpatient procedure November 17, 2025
Taking a frothy risk to advance gene therapy Fred Hutch scientists hope foam could be a cost-reducing, access-enhancing vehicle for delivering future gene therapies June 3, 2024
Investment in business development pays dividends for research, patients Fred Hutch tech transfer specialists help scientists navigate path to bringing innovations to patients September 2, 2021